Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older : Interim recommendation.
'The objective of this Statement Update is to provide evidence and interim recommendations for the use of PNEU-C-13 in immunocompetent adults over 65 years of age and to allow informed decision making in cases when PNEU-C-13 is being considered on an individual basis for use in this age group. This statement: updates the epidemiology of pneumococcal disease in Canada for strains prevented by PNEU-C-13 to the year of the most recently available data (2013); provides an update to the review of the literature on the use of PNEU-C-13 in immunocompetent adults, which includes the recently published CAPiTA trial, as well as randomised controlled trials (RCTs) that investigate safety and immunogenicity; and provides updated, interim, recommendations for the use of PNEU-C-13 in immunocompetent individuals who are 65 years of age and over“--Introduction (p. 5).
Record details
- ISBN: 9780660058382
- Physical Description: 1 online resource (27 pages).
- Publisher: Ottawa: Public Health Agency of Canada, 2016.
Content descriptions
General Note: | Issued as part of the desLibris documents collection. |
Restrictions on Access Note: | Access restricted to authorized users and institutions. |
Type of Computer File or Data Note: | Electronic monograph in PDF format. |
System Details Note: | Mode of access: World Wide Web. |
Search for related items by subject
Subject: | Clinical medicine Diseases and disorders Health Health sciences Immunology Medical specialties Medicine Pneumococcal conjugate vaccine Pneumococcal vaccine Pneumonia |
Genre: | Electronic books |
Search for related items by series
Electronic resources
- desLibris e-book:
- For Subscription see www.canadianelectroniclibrary.ca
- Document originally acquired from